Kynurenines and multiple sclerosis: The dialogue between the immune system and the central nervous system

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 18270-18282

  Rajda, Cecilia ^a   Majláth, Zsófia ^a   Pukoli, Dániel ^a,b   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Markhot Ferenc County Hospital   (Hungary)

Author keywords

3 dioxygenase; Indoleamine 2; Kynurenine pathway; Multiple sclerosis

Indexed keywords

BERBERINE; CINNABARINIC ACID; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; KYNURENINE AMINOTRANSFERASE; LAQUINIMOD; LEFLUNOMID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINYLALANINE; TAU PROTEIN; TERIFLUNOMID; TRANILAST; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; ENZYME ACTIVITY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; REVIEW; ANIMAL; DISEASE MODEL; IMMUNOMODULATION; METABOLISM;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS; MULTIPLE SCLEROSIS; NEUROIMMUNOMODULATION;

EID: 84938879412     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160818270     Document Type: Review

References (69)

1. Lassmann, H.; Bruck, W.; Lucchinetti, C.F. The immunopathology of multiple sclerosis: An overview. Brain Pathol. 2007, 17, 210-218.
2. Mahad, D.H.; Trapp, B.D.; Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015, 14, 183-193.
3. Nielsen, A.S.; Kinkel, R.P.; Madigan, N.; Tinelli, E.; Benner, T.; Mainero, C. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology 2013, 81, 641-649.
4. Peterson, J.W.; Bo, L.; Mork, S.; Chang, A.; Trapp, B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001, 50, 389-400.
5. Schwarcz, R.; Bruno, J.P.; Muchowski, P.J.; Wu, H.Q. Kynurenines in the mammalian brain: When physiology meets pathology. Nat. Rev. Neurosci. 2012, 13, 465-477.
6. Vecsei, L. Kynurenines in the Brain: From Experiments to Clinics; Nova Science Publishers: Hauppauge, NY, USA, 2005.
7. Leklem, J.E. Quantitative aspects of tryptophan metabolism in humans and other species: A review. Am. J. Clin. Nutr. 1971, 24, 659-672.
8. Han, Q.; Cai, T.; Tagle, D.A.; Li, J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol. Life Sci. 2010, 67, 353-368.
9. Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. J. Neurochem. 1989, 52, 1319-1328.
10. Stone, T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45, 309-379.
11. Prescott, C.; Weeks, A.M.; Staley, K.J.; Partin, K.M. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 2006, 402, 108-112.
12. Rozsa, E.; Robotka, H.; Vecsei, L.; Toldi, J. The Janus-face kynurenic acid. J. Neural. Transm. 2008, 115, 1087-1091.
13. Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: Physiopathological implications. J. Neurosci. 2001, 21, 7463-7473.
14. Marchi, M.; Risso, F.; Viola, C.; Cavazzani, P.; Raiteri, M. Direct evidence that release-stimulating α7 nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem. 2002, 80, 1071-1078.
15. Stone, T.W.; Perkins, M.N. Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72, 411-412.
16. Perez-De La Cruz, V.; Carrillo-Mora, P.; Santamaria, A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int. J. Tryptophan Res. 2012, 5, 1-8.
17. Guillemin, G.J.; Cullen, K.M.; Lim, C.K.; Smythe, G.A.; Garner, B.; Kapoor, V.; Takikawa, O.; Brew, B.J. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 2007, 27, 12884-12892.
18. Guillemin, G.J.; Kerr, S.J.; Smythe, G.A.; Smith, D.G.; Kapoor, V.; Armati, P.J.; Croitoru, J.; Brew, B.J. Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. J. Neurochem. 2001, 78, 842-853.
19. Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Kynurenines in the CNS: Recent advances and new questions. Nat. Rev. Drug Discov. 2013, 12, 64-82.
20. Mandi, Y.; Vecsei, L. The kynurenine system and immunoregulation. J. Neural. Transm. 2012, 119, 197-209.
21. Fallarino, F.; Grohmann, U.; Vacca, C.; Bianchi, R.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9, 1069-1077.
22. Belladonna, M.L.; Puccetti, P.; Orabona, C.; Fallarino, F.; Vacca, C.; Volpi, C.; Gizzi, S.; Pallotta, M.T.; Fioretti, M.C.; Grohmann, U. Immunosuppression via tryptophan catabolism: The role of kynurenine pathway enzymes. Transplantation 2007, 84, S17-S20.
23. Gonzalez, A.; Varo, N.; Alegre, E.; Diaz, A.; Melero, I. Immunosuppression routed via the kynurenine pathway: A biochemical and pathophysiologic approach. Adv. Clin. Chem. 2008, 45, 155-197.
24. Paterson, P.Y. Autoimmune diseases of myelin. Prog. Clin. Biol. Res. 1980, 49, 19-36.
25. Gold, R.; Linington, C.; Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129, 1953-1971.
26. Kwidzinski, E.; Bunse, J.; Aktas, O.; Richter, D.; Mutlu, L.; Zipp, F.; Nitsch, R.; Bechmann, I. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 2005, 19, 1347-1349.
27. Chiarugi, A.; Cozzi, A.; Ballerini, C.; Massacesi, L.; Moroni, F. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 2001, 102, 687-695.
28. Flanagan, E.M.; Erickson, J.B.; Viveros, O.H.; Chang, S.Y.; Reinhard, J.F., Jr. Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis. J. Neurochem. 1995, 64, 1192-1196.
29. Cammer, W. Oligodendrocyte killing by quinolinic acid in vitro. Brain Res. 2001, 896, 157-160.
30. Guillemin, G.J.; Wang, L.; Brew, B.J. Quinolinic acid selectively induces apoptosis of human astrocytes: Potential role in AIDS dementia complex. J. Neuroinflamm. 2005, 2, 16.
31. Kerr, S.J.; Armati, P.J.; Guillemin, G.J.; Brew, B.J. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with aids dementia complex. AIDS 1998, 12, 355-363.
32. Pierozan, P.; Zamoner, A.; Soska, A.K.; Silvestrin, R.B.; Loureiro, S.O.; Heimfarth, L.; Mello e Souza, T.; Wajner, M.; Pessoa-Pureur, R. Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exp. Neurol. 2010, 224, 188-196.
33. Monaco, F.; Fumero, S.; Mondino, A.; Mutani, R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. J Neurol. Neurosurg. Psychiatry 1979, 42, 640-641.
34. Rudzite, V.; Berzinsh, J.; Grivane, I.; Fuchs, D.; Baier-Bitterlich, G.; Wachter, H. Serum tryptophan, kynurenine, and neopterin in patients with Guillain-Barre-syndrome (GBS) and multiple sclerosis (MS). Adv. Exp. Med. Biol. 1996, 398, 183-187.
35. Sandyk, R. Tryptophan availability and the susceptibility to stress in multiple sclerosis: A hypothesis. Int. J. Neurosci. 1996, 86, 47-53.
36. Sadowska-Bartosz, I.; Adamczyk-Sowa, M.; Gajewska, A.; Bartosz, G. Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment. J. Neuroimmunol. 2014, 266, 67-74.
37. Anderson, J.M.; Hampton, D.W.; Patani, R.; Pryce, G.; Crowther, R.A.; Reynolds, R.; Franklin, R.J.; Giovannoni, G.; Compston, D.A.; Baker, D.; et al.. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008, 131, 1736-1748.
38. Beck, J.; Rondot, P.; Catinot, L.; Falcoff, E.; Kirchner, H.; Wietzerbin, J. Increased production of interferon γ and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol. Scand. 1988, 78, 318-323.
39. Pemberton, L.A.; Kerr, S.J.; Smythe, G.; Brew, B.J. Quinolinic acid production by macrophages stimulated with IFN-γ, TNF-α, and IFN-α. J. Interferon Cytokine Res. 1997, 17, 589-595.
40. Smith, D.G.; Guillemin, G.J.; Pemberton, L.; Kerr, S.; Nath, A.; Smythe, G.A.; Brew, B.J. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, nef and tat. J. Neurovirol. 2001, 7, 56-60.
41. Guillemin, G.J.; Smith, D.G.; Smythe, G.A.; Armati, P.J.; Brew, B.J. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 2003, 527, 105-112.
42. Guillemin, G.J.; Kerr, S.J.; Pemberton, L.A.; Smith, D.G.; Smythe, G.A.; Armati, P.J.; Brew, B.J. IFN-β1b induces kynurenine pathway metabolism in human macrophages: Potential implications for multiple sclerosis treatment. J. Interferon Cytokine Res. 2001, 21, 1097-1101.
43. Hartai, Z.; Klivenyi, P.; Janaky, T.; Penke, B.; Dux, L.; Vecsei, L. Kynurenine metabolism in multiple sclerosis. Acta Neurol. Scand. 2005, 112, 93-96.
44. Kepplinger, B.; Baran, H.; Kainz, A.; Ferraz-Leite, H.; Newcombe, J.; Kalina, P. Age-related increase of kynurenic acid in human cerebrospinal fluid-IgG and β2-microglobulin changes. Neuro Signals 2005, 14, 126-135.
45. Lim, C.K.; Brew, B.J.; Sundaram, G.; Guillemin, G.J. Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int. J. Tryptophan Res. 2010, 3, 157-167.
46. Rejdak, K.; Bartosik-Psujek, H.; Dobosz, B.; Kocki, T.; Grieb, P.; Giovannoni, G.; Turski, W.A.; Stelmasiak, Z. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 2002, 331, 63-65.
47. Rejdak, K.; Petzold, A.; Kocki, T.; Kurzepa, J.; Grieb, P.; Turski, W.A.; Stelmasiak, Z. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural. Transm. 2007, 114, 1011-1015.
48. Paul, C.; Bolton, C. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. J. Pharmacol. Exp. Ther. 2002, 302, 50-57.
49. Stone, T.W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Exp. Opin. Investig. Drugs 2001, 10, 633-645.
50. Chiarugi, A.; Carpenedo, R.; Molina, M.T.; Mattoli, L.; Pellicciari, R.; Moroni, F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem. 1995, 65, 1176-1183.
51. Colabroy, K.L.; Zhai, H.; Li, T.; Ge, Y.; Zhang, Y.; Liu, A.; Ealick, S.E.; McLafferty, F.W.; Begley, T.P. The mechanism of inactivation of 3-hydroxyanthranilate-3,4-dioxygenase by 4-chloro-3-hydroxyanthranilate. Biochemistry 2005, 44, 7623-7631.
52. Walsh, H.A.; O'Shea, K.C.; Botting, N.P. Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 2003, 4, 13.
53. Platten, M.; Ho, P.P.; Youssef, S.; Fontoura, P.; Garren, H.; Hur, E.M.; Gupta, R.; Lee, L.Y.; Kidd, B.A.; Robinson, W.H.; et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310, 850-855.
54. Bruck, W.; Wegner, C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 2011, 306, 173-179.
55. Fernandez, O. Oral laquinimod treatment in multiple sclerosis. Neurologia 2011, 26, 111-117.
56. Polman, C.; Barkhof, F.; Sandberg-Wollheim, M.; Linde, A.; Nordle, O.; Nederman, T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64, 987-991.
57. Gurevich, M.; Gritzman, T.; Orbach, R.; Tuller, T.; Feldman, A.; Achiron, A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221, 87-94.
58. Zou, L.P.; Abbas, N.; Volkmann, I.; Nennesmo, I.; Levi, M.; Wahren, B.; Winblad, B.; Hedlund, G.; Zhu, J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42, 731-739.
59. Wegner, C.; Stadelmann, C.; Pfortner, R.; Raymond, E.; Feigelson, S.; Alon, R.; Timan, B.; Hayardeny, L.; Bruck, W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227, 133-143.
60. Aharoni, R.; Saada, R.; Eilam, R.; Hayardeny, L.; Sela, M.; Arnon, R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2012, 251, 14-24.
61. Schulze-Topphoff, U.; Shetty, A.; Varrin-Doyer, M.; Molnarfi, N.; Sagan, S.A.; Sobel, R.A.; Nelson, P.A.; Zamvil, S.S. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 2012, 7, e33797.
62. Weber, M.S.; Prod'homme, T.; Youssef, S.; Dunn, S.E.; Rundle, C.D.; Lee, L.; Patarroyo, J.C.; Stuve, O.; Sobel, R.A.; Steinman, L.; et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 2007, 13, 935-943.
63. Comi, G.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A.; Rocca, M.A.; Filippi, M. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Eng. J. Med. 2012, 366, 1000-1009.
64. Sundaram, G.; Brew, B.J.; Jones, S.P.; Adams, S.; Lim, C.K.; Guillemin, G.J. Quinolinic acid toxicity on oligodendroglial cells: Relevance for multiple sclerosis and therapeutic strategies. J. Neuroinflamm. 2014, 11, 1-11.
65. Fazio, F.; Lionetto, L.; Molinaro, G.; Bertrand, H.O.; Acher, F.; Ngomba, R.T.; Notartomaso, S.; Curini, M.; Rosati, O.; Scarselli, P.; et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol. Pharmacol. 2012, 81, 643-656.
66. Fallarino, F.; Volpi, C.; Fazio, F.; Notartomaso, S.; Vacca, C.; Busceti, C.; Bicciato, S.; Battaglia, G.; Bruno, V.; Puccetti, P.; et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat. Med. 2010, 16, 897-902.
67. Fazio, F.; Zappulla, C.; Notartomaso, S.; Busceti, C.; Bessede, A.; Scarselli, P.; Vacca, C.; Gargaro, M.; Volpi, C.; Allegrucci, M.; et al. Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology 2014, 81, 237-243.
68. Anderson, G.; Rodriguez, M. Multiple sclerosis, seizures, and antiepileptics: Role of IL-18, IDO, and melatonin. Eur. J. Neurol. 2011, 18, 680-685.
69. Gonsette, R.E. Endogenous neuroprotection in multiple sclerosis. Acta Neurol. Belg. 2010, 110, 26-35.